Semaglutide (Compounded)

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of compounds originally developed for type 2 diabetes and later studied extensively for weight management. It is best known through branded products such as Wegovy, Ozempic, and the oral tablet Rybelsus.

“Compounded” semaglutide refers to a version prepared by a compounding pharmacy rather than a commercial manufacturer. It is typically supplied as a lyophilized (freeze-dried) powder in a vial that is reconstituted with bacteriostatic water before use. The active molecule is the same semaglutide, but the formulation, concentration, and quality control differ from the FDA-approved branded products.

Semaglutide is among the most heavily studied compounds in this category, with large randomized trials in both diabetes and obesity. It is important to note that compounded formulations themselves have not been individually evaluated by the FDA, even though the underlying molecule is well characterized.

How it works

As a GLP-1 receptor agonist, semaglutide mimics the naturally occurring incretin hormone GLP-1. It acts on receptors in the brain — particularly appetite-regulating centers in the hypothalamus — to increase satiety and reduce hunger, and it slows gastric emptying so that meals feel more filling for longer. Together these effects are commonly reported to lower overall food intake.

Semaglutide also stimulates glucose-dependent insulin secretion and reduces glucagon release, which is the basis for its use in blood-sugar management. Its structure is designed for a long duration of action, which is why the injectable forms are typically dosed once weekly.

Reported benefits

• Meaningful weight reduction, studied for in large randomized obesity trials such as STEP 1
• Reduced appetite and food cravings, commonly reported by users
• Improved glycemic control in people with type 2 diabetes (studied for the branded products)
• Cardiovascular risk reduction in certain higher-risk populations (reported in the branded label)

These are reported and studied outcomes, not guaranteed results, and most clinical evidence comes from the FDA-approved branded formulations rather than compounded versions.

Considerations & side effects

The most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal discomfort — which are often most noticeable when starting or increasing a dose. The prescribing information for branded semaglutide also carries a boxed warning regarding thyroid C-cell tumors observed in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Compounded semaglutide carries additional uncertainty: because these preparations are not FDA-reviewed, potency, purity, and sterility can vary between pharmacies, and errors in reconstitution or dosing have been a documented concern. It is not a substitute for evaluation and treatment by a qualified clinician.